Propanc Biopharma, Inc. (PPCB) Stock Price & Analysis
Propanc Biopharma, Inc. (PPCB) closed at USD 0.34 on Thursday, October 15, 2026, down 6.62% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 0.37; the Oct 15, 2026 session ranged USD 0.33–0.37 on volume of 165,118 shares. Market capitalization is $3.36M, with a 52-week range of USD 0.33–41.25 (NCM). Source: Nexqual, retrieved October 16, 2026 at 05:11 UTC.
Also available as compact Markdown for AI agents: nexqual.com/PPCB.md
Key facts (PPCB)
- Analysts: None.
- Total return with dividends: 1Y -99.1% vs S&P 500 +18.1%; 5Y -100.0% vs S&P 500 +85.1%.
Analysts (PPCB)
Consensus None.
Total return (dividends reinvested) (PPCB)
| 1Y (from 2025-10-16) | 5Y (from 2021-10-11) | |
|---|---|---|
| Total return | -99.1% | -100.0% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | -99.2% | -81.0% |
| Volatility (annualized) | 159.6% | 477.7% |
| Max drawdown | -99.2% (Oct 2025→Oct 2026) | -100.0% (Dec 2021→Dec 2024) |
Key Statistics (as of October 16, 2026 at 05:11 UTC)
| Price | USD 0.34 |
|---|---|
| Change | ▼ 6.62% (down) |
| Previous Close | USD 0.37 |
| Open | USD 0.36 |
| Day Range | USD 0.33 – 0.37 |
| 52-Week Range | USD 0.33 – 41.25 |
| Volume | 165,118 shares |
| Market Cap | $3.36M |
| Exchange | NCM |
Technical Analysis (PPCB)
Nexqual's technical model rates PPCB "SELL" based on 2 bullish and 5 bearish signals across 127 daily candles, as of October 16, 2026 at 05:11 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 10.55 (oversold) |
| vs SMA50 | Below (USD 0.88) |
| MACD | -0.14 (negative) |
Analyst Ratings (PPCB)
Wall Street analysts rate PPCB "None", per Nexqual as of October 16, 2026 at 05:11 UTC.
| Consensus Rating | None |
|---|
Earnings (PPCB)
Source: Nexqual, October 16, 2026 at 05:11 UTC.
Financials & Fundamentals (PPCB)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -161.86% |
| Debt / Equity | 0.05 |
| Current Ratio | 2.55 |
| Total Cash | $832,006 |
| Total Debt | $509,116 |
Source: Nexqual, October 16, 2026 at 05:11 UTC.
Financial Health Score (PPCB)
Nexqual rates Propanc Biopharma, Inc.'s overall financial health "Mixed" across five dimensions, as of October 16, 2026 at 05:11 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $832K cash, no debt |
| Cash Flow | Weak — Operating cash flow -$6M (TTM) |
| Efficiency | Critical — ROE -162%, ROA -70.1% |
Ownership (PPCB)
| Insider Ownership | +62.21% |
|---|---|
| Institutional Ownership | +0.76% |
| Shares Outstanding | 9.83M |
| Float | 5.40M |
| Short % of Float | +1.30% |
Source: Nexqual, October 16, 2026 at 05:11 UTC.
Leadership (PPCB)
Propanc Biopharma, Inc. is led by James Nathanielsz (age 51), CEO & Executive Chairman, per Nexqual as of October 16, 2026 at 05:11 UTC.
| CEO & Executive Chairman | James Nathanielsz (age 51) |
|---|---|
| Chief Financial Officer | Jeannine Zimmerman (age 48) |
Major Backers & Investors (PPCB)
Notable institutional backers of Propanc Biopharma, Inc. include Jane Street Group, LLC, Citadel, according to Nexqual as of October 16, 2026 at 05:11 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Jane Street Group, LLC | 0.25% |
| Citadel | 0.12% |
Source: Nexqual, October 16, 2026 at 05:11 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| RYTM | Rhythm Pharmaceuticals, Inc. | USD 87.97 | ▲ 1.57% |
| BLTE | Belite Bio, Inc | USD 152.62 | ▲ 0.49% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 14.72 | ▲ 1.52% |
| PRAX | Praxis Precision Medicines, Inc | USD 248.24 | ▲ 2.01% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 44.12 | ▲ 4.11% |
| SYRE | Spyre Therapeutics, Inc. | USD 80.1 | ▼ 0.44% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 16, 2026 at 05:11 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt